Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model

Transfusion

Volumn 47, Issue 2, 2007, Pages 240-247

  Rentas, Francisco ^a   Harman, Ronald ^b   Gomez, Charlotte ^b   Salata, Jeanne ^b   Childs, Joseph ^b   Silva, Tonya ^b   Lippert, Lloyd ^b   Montgomery, Joshua ^b   Richards, Allen ^b   Chan, Chye ^b   Jiang, Ju ^b   Reddy, Heather ^b   Li, John ^b   Goodrich, Raymond ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BREATHING; CONTROLLED STUDY; ERYTHROCYTE; GIEMSA STAIN; INFECTION COMPLICATION; INOCULATION; LABOR; LETHARGY; LIGHT; MOUSE; NONHUMAN; PLASMA; REAL TIME POLYMERASE CHAIN REACTION; RICKETTSIA; THROMBOCYTE;

ANIMALS; ANIMALS, OUTBRED STRAINS; BIOLOGICAL ASSAY; BLOOD BANKS; BLOOD PLATELETS; BLOOD TRANSFUSION; DISEASE MODELS, ANIMAL; ERYTHROCYTES; HUMANS; LIGHT; MICE; ORIENTIA TSUTSUGAMUSHI; PHOTOSENSITIZING AGENTS; PLASMA; RIBOFLAVIN; SCRUB TYPHUS;

EID: 33846417644     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01094.x     Document Type: Article

References (42)

1. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;251:760-8.
2. Orton SL, Virvos VJ, Williams AE. Validation of selected donor-screening questions: structure, content, and comprehension. Transfusion 2000;40:1407-13.
3. Aprili G, Gandini G, Piccoli P, et al. Detection of an early HIV-1 infection by HIV RNA testing in an Italian blood donor during the preseroconversion window period. Transfusion 2003;43:848-52.
4. Fang CT, Chambers LA, Kennedy J, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion 2005;45:1845-52.
5. Munksgaard L, Albjerg L, Lillevang ST, Gahrn-Hansen B, Georgsen J. Detection of bacterial contamination of platelet components: six years' experience with the BacT/ALERT system. Transfusion 2004;44:1166-73.
6. Benjamin RJ, Mintz PD. Bacterial detection and extended platelet storage: the next step forward. Transfusion 2005;45:1832-5.
7. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003;289:959-62.
8. Epstein JS, Vostal JG. FDA approach to evaluation of pathogen reduction technology. Transfusion 2003;43:1347-50.
9. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19:110-26.
10. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004;18:235-6.
11. Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002;16:61-6.
12. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44:1496-504.
13. Skripchenko A, Wagner SJ, Thompson-Montgomery D, Awatefe H. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties. Transfusion 2006;46:213-9.
14. Zavizion B, Pereira M, de Melo J, et al. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion 2004;44:731-8.
15. McCormick DB. The fate of riboflavin in the mammal. Nutr Rev 1972;30:75-9.
16. Oka M, McCormick DB. Urinary lumichrome-level catabolites of riboflavin are due to microbial and photochemical events and not rat tissue enzymatic cleavage of the ribityl chain. J Nutr 1985;115:496-9.
17. Yang CS, McCormick DB. The photochemical degradation of flavins as influenced by the length and extent of hydroxylation of the side chain. J Am Chem Soc 1965;87:5764.
18. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004;80:15-21.
19. Corbin F. Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol 2002;76(Suppl 2):253-7.
20. Goodrich RP, Edrich R, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
21. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877-85.
22. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004;87:82-90.
23. Reddy H, Doane S, McLean R, McDaniel S, Dawson L. Riboflavin and visible light inactivate HIV IIIB and a hepatitis C analog (BVDV) in RBC suspension. Vox Sang 2002;83:119.
24. Reddy H, Doane S, McDaniel S, Dawson L, McLean R. Inactivation of intracellular human immunodeficiency virus with riboflavin and visible light. Transfusion 2002;42:93S.
25. Kelly DJ, Richards AL, Temenak J, et al. The past and present threat of rickettsial diseases to military medicine and international public health. Clin Infect Dis 2002;34:S145-S169.
26. Olson JG, Bourgeois AL. Rickettsia tsutsugamushi infection and scrub typhus incidence among Chinese military personnel in the Pescadores Islands. Am J Epidemiol 1977;106:172-5.
27. Leiby DA, Rentas FJ, Nelson KE, et al. Evidence of Trypanosoma cruzi infection (Chagas' disease) among patients undergoing cardiac surgery. Circulation 2000;102:2978-82.
28. Cardo LJ, Rentas FJ, Ketchum L, et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006;90:85-91.
29. Lippert L, Watson R, Doane S, Reddy H, Goodrich RP. Inactivation of P. falciparum by riboflavin and light. Vox Sang 2002;83:163.
30. Brown GW, Robinson DM, Huxsoll DL, et al. Scrub typhus: a common cause of illness in indigenous populations. Trans R Soc Trop Med Hyg 1977;70:444-8.
31. Casleton BG, Salata K, Dasch GA, et al. Recovery and viability of Orientia tsutsugamushi from packed red cells and the danger of acquiring scrub typhus from blood transfusion. Transfusion 1998;38:680-9.
32. Jiang J, Chan TC, Temenak JJ, et al. Development of a quantitative real-time polymerase chain reaction assay specific for Orientia tsutsugamushi. Am J Trop Med Hyg 2004;70:351-6.
33. Ito K, Inoue S, Yamomoto K, et al. 8-hydroxydeoquanisine formation at the 5′ site of 5′-GG-3′ sequences of double stranded DNA by UV radiation with riboflavin. J Biol Chem 1993;269:13221-7.
34. Piper J, Murphy S, Schuyler R, Haynes R, Wilson A. Assessment of the acute toxicity and genotoxicity risks associated with Lumichrome, the primary photoproduct of riboflavin. Vox Sang 2002;83(Suppl 2):192.
35. Reddy H, Dayan AD, Cavagnaro J, et al. Toxicity testing of the Mirasol PRT process for platelets and plasma: a novel riboflavin-based pathogen reduction technology for blood transfusion safety. Transfusion 2007;in press.
36. Khaisuwan S, Kantipong P, Watt G, Burnouf T. Transmission of scrub typhus by blood transfusion? Transfusion 2001;41:1454-5.
37. Mettille FC, Salata KF, Belanger KJ, Casleton BG, Kelly DJ. Reducing the risk of transfusion-transmitted rickettsial disease by WBC filtration, using Orientia tsutsugamushi: a model system. Transfusion 2000;40:290-6.
38. Belanger KJ, Kelly DJ, Mettille FC, Hanson CV, Lippert LE. Psoralen photochemical inactivation of Orientia tsutsugamushi in platelet concentrates. Transfusion 2000;40:1503-7.
39. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45:911-9.
40. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
41. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45:1864-75.
42. Yarranton H, Lawrie AS, Mackie IJ, et al. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion 2005;45:1453-8.